arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Imunon, Inc.

IMNN
$1.49 ▼ -0.01 (-0.33%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
67 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Imunon, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $7.8M
Dividend Yield
Revenue Growth None
Op. Margin
ROIC -52.6%
FCF / Share $-0.58
Trailing P/E
Price / Book 1.7x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$125.00K
— 0.0%
Net Income Profit after all expenses
$-2.81M
↓ -2.7%
FCF / Share Free cash flow per share
$-0.58
↑ +75.1%
Long-Term Debt Long-term obligations
$6.08M
↑ +1.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
2
Cash Quality
65

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 17 years · 67 quarters